Vigonvita Life Sciences 2025: Revenue Jumps 7.63-fold but Loss Widens on Share-Based Payments and IPO Costs

Vigonvita Life Sciences Co., Ltd. reported audited results for the year ended 31 December 2025.

Financial Snapshot • Revenue surged to RMB 102.10 million, up 762.9% year-on-year, driven by the July commercial launch of the erectile-dysfunction drug 昂偉達 (TPN171) and milestone income from licensing VV116 for respiratory syncytial virus (RSV).

• Gross profit rose to RMB 80.68 million, lifting the margin to 79.0% from 29.5% a year earlier.

• A one-off RMB 184.17 million expense from a January restricted-share scheme and RMB 23.11 million listing costs pushed the annual net loss to RMB 357.11 million, a 64.1% widening. Basic loss per share increased to RMB 2.33.

Cash & Balance Sheet • Cash and bank balances reached RMB 447.97 million (2024: RMB 121.14 million), bolstered by HK$587 million gross proceeds from the November Hong Kong IPO. • Net assets climbed to RMB 435.70 million (2024: RMB 140.37 million); current ratio improved to 1.1. • Total borrowings expanded to RMB 599.97 million, leaving a gearing ratio of 0.7.

Cost Structure • R&D expenses grew 50.1% to RMB 202.50 million, reflecting pipeline advancement. • Administrative expenses more than doubled to RMB 163.78 million, largely due to share-based payments. • Selling expenses increased to RMB 45.50 million following the build-out of a 22-person digital marketing team and multi-platform rollout for 昂偉達.

Operational Highlights • TPN171 obtained Chinese marketing approval on 8 July 2025 and began sales in August, contributing RMB 57.84 million. • VV116 dry suspension for RSV completed Phase II trials, secured Breakthrough Therapy Designation and was licensed to Simcere Pharmaceutical, generating upfront and milestone payments. • The company’s first commercial facility in Lianyungang added tablet production capacity for both Rebamipide and 昂偉達. • Patent portfolio expanded with 40 new filings, including six PCT applications.

Pipeline Progress • LV232, a dual-target antidepressant candidate, entered Phase II in March 2025. • IND for premature-ejaculation candidate VV913 received implicit approval in January 2026. • Novel antiviral VV261 and anti-epileptic TPN102 advanced in early-stage clinical development.

Capital Deployment As of year-end, HK$527.40 million net IPO proceeds remained earmarked mainly for clinical programmes, new dosage-form development for TPN171, construction of the Qingdao manufacturing facility, and the expansion of sales capabilities.

Dividend The board recommended no final dividend for 2025.

Outlook Management plans to accelerate pivotal trials, broaden external partnerships and continue capacity expansion to support upcoming product launches while maintaining focus on cost discipline and liquidity.